VEEV:NYE-Veeva Systems Inc. Class A (USD)

EQUITY | Health Information Services | New York Stock Exchange

Last Closing

USD 205.31

Change

+2.17 (+1.07)%

Market Cap

USD 6.08B

Volume

0.92M

Analyst Target

USD 304.05
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Veeva Systems Inc is a provider of industry-specific, cloud-based software solutions for the life sciences industry.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-07 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

-0.59 (-0.98%)

USD 10.78B
DOCS Doximity Inc

+0.87 (+3.13%)

USD 5.16B
EVH Evolent Health Inc

-0.19 (-0.82%)

USD 2.67B
TDOC Teladoc Inc

-0.12 (-1.05%)

USD 1.95B
PHR Phreesia Inc

-0.02 (-0.09%)

USD 1.38B
AGTI Agiliti Inc

N/A

USD 1.37B
WEAV Weave Communications Inc

+0.01 (+0.11%)

USD 0.63B
MPLN MultiPlan Corporation

-0.09 (-12.39%)

USD 0.44B
AMWL American Well Corp

N/A

USD 0.13B
OWLT Owlet Inc

+0.03 (+0.82%)

USD 0.03B

ETFs Containing VEEV

EKG First Trust Nasdaq Lux Di.. 7.27 % 0.00 %

-0.09 (0.45%)

USD 2.42M
CURE:XETRA VanEck Genomics and Healt.. 5.68 % 0.00 %

-0.41 (0.45%)

USD 7.01M
CURG:LSE VanEck Genomics and Healt.. 5.66 % 0.00 %

-0.37 (0.45%)

USD 6.98M
LCG Sterling Capital Focus Eq.. 4.57 % 0.00 %

-0.14 (0.45%)

USD 0.07B
FDOC:LSE Fidelity Digital Health U.. 4.47 % 0.00 %

+0.02 (+0.45%)

USD 4.79M
FDHT:XETRA Fidelity Digital Health U.. 4.36 % 0.00 %

N/A

USD 4.81M
FDHT 4.22 % 0.00 %

N/A

N/A
CLDL Direxion Daily Cloud Comp.. 3.62 % 0.00 %

-0.25 (0.45%)

USD 4.66M
MOAT:LSE VanEck Morningstar US Sus.. 2.52 % 0.00 %

-0.56 (0.45%)

USD 0.50B
MOGB:LSE VanEck Morningstar US Sus.. 2.52 % 0.00 %

-0.59 (0.45%)

USD 0.50B
IHF iShares U.S. Healthcare P.. 0.00 % 0.43 %

-0.34 (0.45%)

USD 0.80B
QRH:CA 0.00 % 1.20 %

N/A

N/A
EASI 0.00 % 0.75 %

N/A

N/A
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

+0.01 (+0.45%)

USD 0.02B
VMOM:XETRA 0.00 % 0.00 %

N/A

N/A
WELP:LSE HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.95 (0.45%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.64% 90% A- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.64% 90% A- 64% D
Trailing 12 Months  
Capital Gain 17.17% 100% F 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.17% 100% F 60% D-
Trailing 5 Years  
Capital Gain 44.50% 67% D+ 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.50% 67% D+ 62% D
Average Annual (5 Year Horizon)  
Capital Gain 14.31% 82% B 79% B-
Dividend Return 14.31% 82% B 76% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 42.00% 64% D 24% F
Risk Adjusted Return 34.06% 91% A- 56% F
Market Capitalization 6.08B 100% F 92% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Health Information Services) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 109.90 43% 10%
Price/Book Ratio 7.18 18% 12%
Price / Cash Flow Ratio 35.12 9% 6%
Price/Free Cash Flow Ratio 63.60 9% 2%
Management Effectiveness  
Return on Equity 12.58% 91% 66%
Return on Invested Capital 8.78% 73% 60%
Return on Assets 5.01% 82% 72%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.